Hydrofluoroalkane (HFA) inhaler propellants
Pro Research Analysisby 
Searched over 200M research papers
Hydrofluoroalkane (HFA) Inhaler Propellants: Environmental and Clinical Perspectives
Transition from CFC to HFA Propellants in Inhalers
Pressurized metered-dose inhalers (pMDIs) originally used chlorofluorocarbons (CFCs) as propellants, but these were phased out due to their ozone-depleting effects. Hydrofluoroalkanes (HFAs), such as HFA-134a and HFA-227, replaced CFCs because they do not harm the ozone layer and are safe for human use, leading to widespread adoption in asthma and COPD treatments 38.
Environmental Impact and the Move to Low-GWP Propellants
While HFAs do not deplete ozone, they have a high global warming potential (GWP), prompting efforts to develop inhalers with lower environmental impact. Newer propellants like HFA-152a and HFO-1234ze(E) are being explored for their much lower GWP. Studies show that HFO-1234ze(E) results in negligible formation of persistent environmental byproducts, making it a promising alternative 467. The pharmaceutical industry is actively reformulating pMDIs to use these low-GWP propellants, balancing environmental concerns with patient needs 78.
Drug Delivery Performance and Safety of HFA Propellants
HFA-based inhalers have been shown to deliver medication more consistently than older CFC devices, with improved dosing reproducibility and stability throughout the canister’s life. Patients using HFA inhalers tend to use fewer canisters per year compared to those using CFC inhalers, suggesting more efficient drug delivery and potential cost savings .
Recent clinical trials comparing HFA-152a to HFA-134a found equivalent safety and no increased risk of bronchoconstriction, supporting the transition to lower-GWP propellants without compromising patient safety 49. In vitro and in vivo studies confirm that new low-GWP propellants can match the aerodynamic performance of current HFA-based inhalers .
Formulation Challenges and Advances
Formulating drugs with HFA propellants presents unique challenges. Traditional surfactants used with CFCs are often insoluble in HFAs, requiring new surfactants or co-solvents to stabilize drug suspensions. The polarity and accessibility of functional groups in excipients play a key role in stabilizing drug-propellant mixtures, guiding the design of new formulations 15. For some drugs, dissolving them directly in HFA with co-solvents can simplify formulation and avoid suspension issues .
Innovative drug delivery systems, such as reverse water-in-fluorocarbon emulsions, have also been developed using HFA propellants, enabling the delivery of both small molecules and biomolecules to the lungs 110.
Conclusion
Hydrofluoroalkane (HFA) propellants have successfully replaced CFCs in inhalers, offering safe and effective drug delivery with no ozone depletion. However, their high global warming potential is driving the development of next-generation, low-GWP propellants like HFA-152a and HFO-1234ze(E). These new propellants show promise for maintaining clinical performance and safety while significantly reducing environmental impact. Ongoing research and innovation in formulation science are ensuring that inhaler therapies remain both effective for patients and sustainable for the environment 12345678+2 MORE.
Sources and full results
Most relevant research papers on this topic